Adverum Biotechnologies, Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form 15 / Schedule TO; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$128M
Investors
20
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Adverum Biotechnologies, Inc. is an entity organized in Delaware that first filed a Form D on April 28, 2014 and most recently amended it on December 19, 2025. The offering claims Securities Exchange Act of 1934. Adverum Biotechnologies, Inc. reported $127,800,000 sold from 20 investors as of the Form D filed December 19, 2025. The Form D names Cowen and Company, LLC (CRD 7616), associated with None; Truist Securities, Inc. (CRD 6271), associated with None as recipients of sales compensation soliciting in CA, NY. The issuer's address of record is 100 Cardinal Way, Redwood City, CA 94063.
EDGAR Filing Data
Form 15 / Schedule TO — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
5
latest Dec 19, 2025
Critical / warning
0 / 1
3 watch · 1 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
closed
Latest event Exchange act deregistration · Dec 19, 2025
SEC.govInvestor
- 5 filing events with values and deltas, latest 2025-12-19, and alerts on the next one
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2024-02-21: 13 related persons added and 8 removed against the filing of 2014-09-08; 13 now listed. The names are in the Terminal feed.
Laurent Fischer
Executive Officer, Director · Redwood City, CA
Linda Rubinstein
Executive Officer · Redwood City, CA
Patrick Machado
Director · Redwood City, CA
Soo Hong
Director · Redwood City, CA
Mark Lupher
Director · Redwood City, CA
C. David Nicholson
Director · Redwood City, CA
Rabia Gurses Ozden
Director · Redwood City, CA
James Gurses Scopa
Director · Redwood City, CA
Dawn Gurses Svoronos
Director · Redwood City, CA
Reed Gurses Tuckson
Director · Redwood City, CA
Scott Gurses Whitcup
Director · Redwood City, CA
Setareh Gurses Seyedkazemi
Executive Officer · Redwood City, CA
Kishor Peter Soparkar
Executive Officer · Redwood City, CA
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Cowen and Company, LLCCRD 7616 on BrokerCheck
Associated broker-dealer: None · New York, NY · Soliciting in CA, NY
Truist Securities, Inc.CRD 6271 on BrokerCheck
Associated broker-dealer: None · Atlanta, GA · Soliciting in CA, NY
Questions About Adverum Biotechnologies, Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Adverum Biotechnologies, Inc.?
Adverum Biotechnologies, Inc. is an issuer that filed a Form D with the SEC on December 19, 2025. The filing claims Securities Exchange Act of 1934.
Is Adverum Biotechnologies, Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. Adverum Biotechnologies, Inc. filed a Form D with the SEC on December 19, 2025 claiming Securities Exchange Act of 1934. A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $127,800,000 sold to 20 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Adverum Biotechnologies, Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Adverum Biotechnologies, Inc. claimed Securities Exchange Act of 1934 and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Adverum Biotechnologies, Inc. raised?
Adverum Biotechnologies, Inc. reported $127,800,000 sold from 20 investors as of the Form D filed December 19, 2025.
Who is selling Adverum Biotechnologies, Inc. and how are they paid?
The Form D names Cowen and Company, LLC (CRD 7616), associated with None; Truist Securities, Inc. (CRD 6271), associated with None as recipients of sales compensation soliciting in CA, NY.
Who is behind Adverum Biotechnologies, Inc.?
The Form D lists 13 related persons: Laurent Fischer, executive officer, director; Linda Rubinstein, executive officer; Patrick Machado, director; Soo Hong, director; Mark Lupher, director; C. David Nicholson, director; Rabia Gurses Ozden, director; James Gurses Scopa, director, and 5 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Adverum Biotechnologies, Inc. located?
The issuer's address on its SEC filings is 100 Cardinal Way, Redwood City, CA 94063. Its phone number of record is (650) 649-1004. It is organized under the laws of Delaware.
How long is the Adverum Biotechnologies, Inc. offering open?
An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.

Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
